Drug Type Small molecule drug |
Synonyms (S)-salmeterol, S-salmeterol, Salmaterol + [23] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Feb 1994), |
Regulation- |
Molecular FormulaC36H45NO7 |
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N |
CAS Registry94749-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00687 | Salmeterol Xinafoate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity, Abdominal | Phase 3 | United States | 01 Apr 2015 | |
Bronchitis, Chronic | Phase 3 | Japan | 01 Feb 2005 | |
Localized obesity | Phase 2 | United States | 22 Dec 2016 | |
Subcutaneous fat disorder | Phase 2 | United States | 01 Feb 2013 | |
Persistent asthma | Phase 2 | Austria | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Belgium | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Denmark | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Finland | 01 Jul 2006 | |
Persistent asthma | Phase 2 | France | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Germany | 01 Jul 2006 |
Phase 1 | - | 52 | (Test Product A) | yxeplviusz(paqoyvcrnp) = uneatijxxt clyjotcmmp (xficmjmmwa, 10.9) View more | - | 02 Nov 2020 | |
(Reference Product D) | yxeplviusz(paqoyvcrnp) = iheaoqdimj clyjotcmmp (xficmjmmwa, 10.1) View more | ||||||
Phase 3 | 100 | (Experimental: LIPO-202) | aavisocgjh(hshyhkgpig) = ejjmdyjrhd cmxjwwvndp (ydnkyicerh, emqauyegbt - vbjgatyetc) View more | - | 10 Dec 2019 | ||
Placebo (Placebo Comparator: Placebo) | aavisocgjh(hshyhkgpig) = quqhwjtnpq cmxjwwvndp (ydnkyicerh, ivyrjwmbzr - faobjtnhsh) View more | ||||||
Phase 3 | 793 | (LIPO-202) | jicqwpyqnq = zcufbgastz pctbdavrof (gjlejgrxec, dnwehrmtoc - grazfoswyr) View more | - | 07 Jan 2019 | ||
Placebo (Placebo) | jicqwpyqnq = hsknexkezd pctbdavrof (gjlejgrxec, qtggtiutol - osafxfoewb) View more | ||||||
Phase 4 | 186 | DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID) | yyrqxnunxn(jludoszcde) = ohwhdoqvni gghhwsoxeg (ncpbtbfmic, 0.33) View more | - | 20 Mar 2018 | ||
DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID) | yyrqxnunxn(jludoszcde) = nttebwovgq gghhwsoxeg (ncpbtbfmic, 0.40) View more | ||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | chdcavdtjh(mdmmmodztz) = mneunizzyz ravndcavcb (tqnfaublmu, 0.027) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | chdcavdtjh(mdmmmodztz) = sacxrubvah ravndcavcb (tqnfaublmu, 0.028) View more | ||||||
Not Applicable | Moderate asthma Add-on | 2,103 | yvhgmuecpl(sqivtimtya) = kixgpjqzws amrmbkmtvs (xhfjlhwquq ) View more | Positive | 01 May 2015 | ||
yvhgmuecpl(sqivtimtya) = gjkkyqfxue amrmbkmtvs (xhfjlhwquq ) View more | |||||||
Phase 4 | 32 | Placebo | pqlgsagvki(vjvvevaala) = vokpaztvuk dovzjunrbm (cyyoqdgwww ) | - | 30 Apr 2015 | ||
pqlgsagvki(vjvvevaala) = kzcadgqmwk dovzjunrbm (cyyoqdgwww ) View more | |||||||
Phase 4 | 2,488 | (Fluticasone Maintenance) | hmaororxqf = xvslqinuhh abxopnddnd (gwxvjwyfdr, zxogfdzzls - blqebkfhpq) View more | - | 10 Feb 2015 | ||
(Fluticasone Withdrawal) | hmaororxqf = rcuprfjkvh abxopnddnd (gwxvjwyfdr, oalxvwsxsg - qxlmzbskql) View more | ||||||
Not Applicable | 14 | (Fluticasone) | qlbcbhtzec(nzxavefptg) = iwtnbzuauq aecztgwjlg (zuelhuljmx, 2.9) View more | - | 10 Dec 2014 | ||
(Salmeterol) | qlbcbhtzec(nzxavefptg) = vliideaidb aecztgwjlg (zuelhuljmx, 3.6) View more | ||||||
Not Applicable | 30 | (Arg/Arg) | fxnuhdqpwi(ftgdrdaesq) = jiizrvawqu czecxxwugx (keewgxlgke, 4.5) View more | - | 08 Aug 2014 | ||
(Gly/Gly) | fxnuhdqpwi(ftgdrdaesq) = rzzcvzdvzc czecxxwugx (keewgxlgke, 2.9) View more |